Antibody-Drug Conjugates (ADCs) – known as ‘the guided missiles of cancer therapy’ – are forecast to drive robust double-digit growth in contract development and manufacturing over the coming years, positioning them as a pivotal force in the biopharmaceutical landscape. ADCs
CARBOGEN AMCIS, a Switzerland-based pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, has successfully completed U.S. Food and Drug Administration (FDA) inspections at its Neuland and Aarau sites. The inspections, conducted in June 2024, concluded with no Form
CARBOGEN AMCIS Contract Manufacturing & Development (CDMO) Profile CARBOGEN AMCIS provides drug development and commercialisation services to the pharmaceutical and biopharmaceutical industries, at all stages of drug development. Our capabilities span from contract chemical process research and development to the
In the latest episode of the PharmaSource CDMO Sessions, we speak Stephan Fritchi, Executive Vice President Business Units for CARBOGEN AMCIS.
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
